Purpose/Objectives: To describe the organizational designs and task environments of community oncology networks with high accrual rates to cancer prevention clinical trials.
Design: Replicated case study design; structural contingency theory. Setting: Local Community Clinical Oncology Programs (CCOPs) funded by the National Cancer Institute to test preventive and therapeutic interventions in community settings.
Sample: Primary sample: oncology professionals affi liated with four CCOPs ranking among the top 10 in earned cancer control accrual credits in fi scal years 1999-2003. Secondary sample: oncology professionals affi liated with three CCOPs ranking among the top 10 three to four times during the study period. A total of 63 people participated in the interviews.
Methods: Primary sample: on-site interviews with CCOP investigators, clinical research staff, and nononcology physicians. Secondary sample: telephone interviews with each CCOP's nurse administrator and at least one prevention research nurse.
Main Research Variables: Staffing patterns, organizational processes, recruitment strategies, and environmental characteristics.
Findings: All of the CCOPs employed dedicated prevention research staff. Recruitment through media publicity, mass mailings, or group information sessions worked best when prevention trials had fl exible eligibility requirements and evaluated interventions with few health risks. Prevention trials evaluating agents with known toxicities in high-risk populations required more targeted recruitment through cancer screening programs, physician referral networks, and one-on-one discussions with protocol candidates.
Conclusions: High-performing CCOPs confi gured their structures, processes, and recruitment strategies to fi t with accrual goals. They also benefi ted from stable and supportive task environments.
Implications for Nursing: Nurse-coordinated research networks have great potential to generate new knowledge about cancer prevention that can reduce cancer incidence and mortality signifi cantly.
M
ajor advances in the molecular study of neoplasia, cancer risk assessments, and molecular-targeted drug development have established cancer prevention as an exceptionally promising area for scientifi c investigation and clinical practice (Lippman & Levin, 2005) . Although expanded treatment options and improved medical management are helping patients with cancer live longer and better, interventions designed to prevent, arrest, or reverse the carcinogenesis process offer the greatest hope for reducing cancer incidence, morbidity, and mortality (Ford et al., 2003) . Byers et al. (1999) estimated that, with accelerated efforts to develop and implement preventive interventions, the United States could achieve a 19% decline in cancer incidence rates by 2015 and a 29% decline below the 1990 levels in cancer mortality rates. In absolute numbers, such interventions could prevent approximately 100,000 cases of cancer and 60,000 deaths from cancer each year.
The expanding scope of cancer prevention research has created opportunities for oncology nurses to lend their expertise to prevention clinical trials and to educate patients about evidence-based prevention strategies (Bailey, Bieniasz, Kmak, Brenner, & Ruffi n, 2004; Jennings-Dozier & Mahon, 2000; Loescher, 2004; Oncology Nursing Society, 2001) . Cancer centers and clinical cooperative groups increasingly are partnering with local networks of oncology professionals to assess the effectiveness of chemopreventive agents in reducing cancer risk and the diagnostic effi cacy of new screening technologies (Hawk, Umar, & Viner, 2004; Lippman & Hong, 2002; Weiner, McKinney, & Carpenter, 2006) . Community oncology networks already engaged in cancer treatment research This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.
